In the News

Sino Biopharm Completes F-Star Acquisition After US CFIUS Review, Scrip

Friday, March 10, 2023

Partner David Plotinsky is featured in an article from Pharma Intelligence’s Scrip covering Committee on Foreign Investment in the United States (CFIUS) clearance of China-related life sciences transactions.

“Given the heightened scrutiny the US Government is now giving to biotechnology and biomanufacturing, it seems reasonable to assume that life sciences deals with a Chinese acquirer should generally be expected to clear CFIUS, if at all, only with mitigation,” David said.

Read the full Scrip article >>

Subscription may be required.